<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0028-3746</journal-id>
<journal-title><![CDATA[Neumología y cirugía de tórax]]></journal-title>
<abbrev-journal-title><![CDATA[Neumol. cir. torax]]></abbrev-journal-title>
<issn>0028-3746</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Neumología y Cirugía de Tórax; Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas; Sociedad Cubana de Neumología; Sociedad Paraguaya de Neumología; Sociedad Boliviana de Neumología.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0028-37462020000100026</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Adenocarcinoma pulmonar con rearreglo ALK: un fenotipo clínico y tomográfico distinto]]></article-title>
<article-title xml:lang="en"><![CDATA[ALK-positive lung adenocarcinoma: a different phenotype clinic and tomographic different]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez-Ríos]]></surname>
<given-names><![CDATA[Carla Paola]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez-Cid]]></surname>
<given-names><![CDATA[Jerónimo Rafael]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez-Barrera]]></surname>
<given-names><![CDATA[Luis Manuel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Santillán-Doherty]]></surname>
<given-names><![CDATA[Patricio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alatorre-Alexander]]></surname>
<given-names><![CDATA[Jorge Arturo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2020</year>
</pub-date>
<volume>79</volume>
<numero>1</numero>
<fpage>26</fpage>
<lpage>30</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0028-37462020000100026&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0028-37462020000100026&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0028-37462020000100026&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  El tratamiento del cáncer de pulmón actualmente es un modelo que se rige en la selección de pacientes de acuerdo con la presencia de anormalidades oncogénicas. El gen ALK está presente entre 3 y 7% de los pacientes con cáncer de pulmón de células no pequeñas (CPCNP) y confiere sensibilidad a los inhibidores de ALK.  Objetivo:  Describir el comportamiento clínico y tomográfico de los pacientes con cáncer de pulmón ALK positivo en el Instituto Nacional de Enfermedades Respiratorias.  Material y métodos:  Estudio observacional retrospectivo de pacientes con cáncer de pulmón de enero de 2013 a agosto de 2018. Se revisaron expedientes clínicos y radiológicos con registro de variables sociodemográficas, clínicas y moleculares.  Resultados:  Se analizó una cohorte de 2013 a 2018 con un total de 751 pacientes con diagnóstico de cáncer pulmonar. El CPCNP fue el más frecuente con 93.74% (n = 704). El adenocarcinoma se encontró en 86% (n = 606). Se reportó rearreglo ALK en 3.3% (n = 20). La mayoría eran de género femenino 65% (n = 13), la edad promedio fue de 58 ± 2.4 años, tabaquismo en 40% (n = 8). De los pacientes nunca fumadores 92% (n = 11) reportaron exposición a biomasa. En 25% (n = 5) se documentó enfermedad pulmonar obstructiva crónica. Los patrones tomográficos fueron: masa-consolidación en 70% (n = 14), engrosamiento pleural con derrame pleural en 20% (n = 4) y patrón micronodular en 10% (n = 2).  Conclusiones:  Se demuestra un fenotipo clínico y comportamiento diferente al resto de pacientes con CPCNP en pacientes ALK positivo.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction:  The treatment of lung cancer currently follows a model that is governed by the selection of patients according to the presence of oncogenic abnormalities. The ALK gene is present in 3 to 7% of patients with non-small cell lung cancer (NSCLC) and confers sensitivity to ALK inhibitors.  Objective:  To describe the clinical and tomographic behavior of patients with ALK positive lung cancer in INER.  Material and methods:  A retrospective observational study of patients with lung cancer from January 2013 to August 2018. A review of clinical and radiological records was made, with registration of sociodemographic, clinical and molecular variables.  Results:  A cohort was analyzed from 2013 to 2018 with a total of 751 patients diagnosed with lung cancer. The CPCNP was the most frequent with 93.74% (n = 704). The adenocarcinoma was found in 86% (n = 606). ALK rearrangement was reported in 3.3% (n = 20). The majority were 65% female (n = 13), the average age was 58 ± 2.4 years, smoking 40% (n = 8). Of the patients who never smoked, 92% (n = 11) reported exposure to biomass. In 25% (n = 5) COPD was documented. The tomographic patterns were: mass in 70% (n = 14), pleural thickening with pleural effusion in 20% (n = 4) and micronodular pattern in 10% (n = 2).  Conclusions:  A clinical phenotype and behavior different to the rest of patients with NSCLC is demonstrated in ALK positive patients.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Cáncer pulmonar]]></kwd>
<kwd lng="es"><![CDATA[ALK-rearreglo]]></kwd>
<kwd lng="es"><![CDATA[pronóstico]]></kwd>
<kwd lng="en"><![CDATA[Lung cancer]]></kwd>
<kwd lng="en"><![CDATA[ALK-positive]]></kwd>
<kwd lng="en"><![CDATA[prognosis]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kwak]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bang]]></surname>
<given-names><![CDATA[YJ]]></given-names>
</name>
<name>
<surname><![CDATA[Camidge]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2010</year>
<volume>363</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>1693-703</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camidge]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Kono]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Flacco]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment]]></article-title>
<source><![CDATA[Clin Cancer Res]]></source>
<year>2010</year>
<volume>16</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>5581-90</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[KY]]></given-names>
</name>
<name>
<surname><![CDATA[Ruestow]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Cowan]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Madl]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lung cancer mutation profile of EGFR, ALK, and KRAS: meta-analysis and comparison of never and ever smokers]]></article-title>
<source><![CDATA[Lung Cancer]]></source>
<year>2016</year>
<volume>102</volume>
<page-range>122-34</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tanaka]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Matsuoka]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sutani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frequency of and variables associated with the EGFR mutation and its subtypes]]></article-title>
<source><![CDATA[Int J Cancer]]></source>
<year>2010</year>
<volume>126</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>651-5</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shaw]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Engelman]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ALK in lung cancer: past, present, and future]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2013</year>
<volume>31</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1105-11</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez-Ríos]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Cid]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Barrera]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Santillán-Doherty]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Alatorre-Alexander]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Descripción clínico-epidemiológica y molecular del cáncer de pulmón en un centro de referencia nacional]]></article-title>
<source><![CDATA[Neumol Cir Torax]]></source>
<year>2019</year>
<volume>78</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>356-62</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yamamoto]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Korn]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Oklu]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization]]></article-title>
<source><![CDATA[Radiology]]></source>
<year>2014</year>
<volume>272</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>568-76</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
